Cannabis and Psoriasis

This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.

Plain-language summary

Psoriasis is a chronic autoimmune disease in which the immune system drives skin cells to multiply too fast, producing thick, scaly, often itchy plaques. The IL-23/IL-17 inflammatory pathway is central to the disease ^[1].

Cannabis contains compounds—THC, CBD, CBG and others—that interact with the endocannabinoid system, which is present in human skin and helps regulate inflammation, keratinocyte (skin cell) proliferation, and immune activity ^[2]. That biological overlap is why researchers are interested. It is not, by itself, evidence that cannabis treats psoriasis.

As of October 2026, no cannabinoid product is approved by the FDA, EMA, or MHRA for psoriasis. Existing human evidence is limited to small case series, surveys, and a handful of small trials on related skin conditions. The strongest claims you see online—that CBD oil 'clears' psoriasis, that cannabis is anti-inflammatory enough to replace biologics—are not supported by the data we have. No data

This article is informational and is not medical advice. Psoriasis can range from a cosmetic annoyance to a disabling, joint-destroying systemic disease. Decisions about treatment should be made with a dermatologist or rheumatologist who knows your case.

What probably works

Honestly: in the cannabis-for-psoriasis space, nothing yet qualifies as 'probably works' by the standards of evidence-based medicine.

There are no large randomized controlled trials, no replicated positive trials, and no regulatory approvals. Anyone telling you otherwise is selling something.

The closest thing to a defensible 'probably' is symptomatic relief of itch and sleep disruption in people who use cannabis for general reasons—but even this rests on indirect evidence from other itch conditions and from cannabis's known effects on sleep, not on psoriasis-specific trials. Weak / limited If you have psoriasis-related insomnia or itch that has not responded to standard topical treatments, discussing low-dose cannabis with your dermatologist may be reasonable; but this is symptom management, not disease control.

What might work (weak or preliminary evidence)

Topical cannabinoids for plaque appearance and itch. A small 2019 open-label study by Palmieri et al. applied a CBD-enriched ointment to psoriasis, atopic dermatitis, and scarring lesions and reported improvements in skin hydration, elasticity, and itch over three months. The study had no control group, no blinding, and a mixed-condition cohort—so it is hypothesis-generating, not confirmatory. Weak / limited

Cannabinoids and keratinocyte proliferation. In cell-culture work, THC, CBD, CBN, and CBG all slowed the proliferation of human keratinocytes—the runaway-cell-division problem at the heart of plaque formation ^[3]. This is mechanistically suggestive but very far from clinical proof. Many compounds suppress keratinocytes in a dish without doing anything useful on a human elbow. Weak / limited

Psoriatic arthritis pain. There is moderate evidence that cannabis can reduce some forms of chronic pain ^[4]. Whether that generalizes to psoriatic arthritis specifically has not been well studied. Weak / limited

Itch (pruritus). Cannabinoid receptors are expressed on sensory neurons and skin immune cells, and small trials of topical cannabinoid-related compounds (e.g. palmitoylethanolamide) have shown antipruritic effects in conditions like uremic itch and atopic dermatitis ^[2]. See Cannabis and Pruritus for detail. Direct psoriasis-itch trials are essentially absent. Weak / limited

What doesn't work, or has no good evidence

• Smoking cannabis to treat psoriasis. No clinical evidence supports this, and smoking introduces its own inflammatory load. Tobacco smoking is an established risk factor for psoriasis severity ^[5]; cannabis smoke shares many combustion products. No data
• Oral CBD as a standalone psoriasis treatment. No published RCTs. Confident marketing claims are not backed by trial data. No data
• 'High-myrcene' or 'indica' strains for autoimmune disease. The indica/sativa label does not reliably predict chemistry or clinical effect Disputed, and no terpene has been shown to modify psoriasis in humans. No data
• Replacing biologics with cannabis. No data exist to support this switch. Stopping a working biologic to switch to CBD carries a real, measurable downside (disease flare, joint damage in psoriatic arthritis) with no demonstrated upside.

What we don't know

A lot. Open questions include:

• Whether topical CBD or THC at any specific concentration outperforms a basic moisturizer in a blinded, placebo-controlled trial.
• Whether cannabinoids modulate the IL-23/IL-17 axis in humans the way they appear to in some animal models.
• Whether oral or inhaled cannabis has any disease-modifying effect, or only changes how patients feel about their disease via pain, itch, sleep, and mood.
• Whether long-term cannabis use interacts (positively or negatively) with methotrexate, cyclosporine, or biologics. See Cannabis and Polypharmacy Risks. CBD is a known inhibitor of CYP enzymes and can raise levels of some co-administered drugs ^[6].
• Whether specific minor cannabinoids (CBG, CBC) or non-cannabinoid skin lipids are doing the work in topical formulations.

Until there are properly powered, placebo-controlled trials, anyone giving you confident numbers is guessing.

Comparison with standard treatments

For context, here is what does have strong evidence in psoriasis:

• Topical corticosteroids and vitamin D analogs (calcipotriol): first-line for mild-to-moderate plaque psoriasis, with decades of trial data and well-characterized toxicity profiles. Strong evidence ^[1]
• Narrowband UVB phototherapy: effective for widespread disease. Strong evidence ^[1]
• Methotrexate, cyclosporine, acitretin: systemic agents with well-documented efficacy and known toxicities requiring monitoring. Strong evidence ^[1]
• Biologics targeting TNF-α (adalimumab), IL-17 (secukinumab, ixekizumab), or IL-23 (guselkumab, risankizumab): produce PASI-90 or PASI-100 responses (near-complete or complete clearance) in a majority of patients in pivotal trials ^[7]. Strong evidence

No cannabis product has demonstrated efficacy approaching these benchmarks in published controlled trials. The difference is not small—it is the difference between an unproven hope and a regulatory approval.

Risks and interactions

• Drug interactions. CBD inhibits CYP3A4 and CYP2C19 and can raise blood levels of drugs metabolized by these pathways. Cyclosporine and some immunosuppressants are CYP3A4 substrates ^[6]. Strong evidence This matters significantly for psoriasis patients on systemics. Discuss cannabis use with your pharmacist or rheumatologist before starting.
• Smoke exposure. Combusted cannabis irritates airways and contributes to general inflammatory burden; tobacco co-use is associated with more severe psoriasis ^[5]. Strong evidence If you use cannabis, consider non-combusted methods (vaporization, topical, oral).
• Topical contact dermatitis. Cannabinoid topicals often contain carrier oils, fragrances, and preservatives that can themselves provoke skin reactions—especially on already-inflamed psoriatic skin. Weak / limited
• Product quality. The CBD market is poorly regulated. FDA testing has repeatedly found products that contain less (or more) cannabinoid than labeled, plus contaminants ^[8]. Strong evidence This matters if you are considering long-term use.
• Replacing effective therapy. The biggest risk is opportunity cost: choosing an unproven cannabis product over a proven treatment for moderate-to-severe disease, which can result in permanent joint damage in psoriatic arthritis. Strong evidence

This article is informational and is not medical advice. Talk to your dermatologist or rheumatologist before changing your treatment.

Sources

How this page was made

Related

• Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
• Cannabis and Post-Surgical Pain — Research on cannabinoids for acute post-surgical pain is limited and mixed; standard multi...
• Cannabis and Pruritus (Itch) — What the evidence says about cannabis for chronic itch and when to see a dermatologist.